Blockchain Registration Transaction Record

Lung Cancer Screening Crisis: Low Rates Despite Deadly Impact

American Lung Association report shows critically low lung cancer screening rates despite 20% of cancer deaths. Survival rates improving to 26.6% with new treatments from companies like Calidi Biotherapeutics.

This news matters because lung cancer remains the leading cause of cancer deaths in the United States, yet most eligible individuals aren't getting screened. Early detection through screening can dramatically improve survival rates and treatment outcomes. The low screening rates represent a massive missed opportunity to save lives and reduce healthcare costs. As new treatments emerge from companies like Calidi Biotherapeutics, the importance of early detection becomes even more critical - advanced therapies work best when cancer is caught early. This affects not only current at-risk individuals but also sets the stage for future public health strategies that could prevent thousands of unnecessary deaths annually.